Venus Medtech (Hangzhou) Inc.

SEHK:2500 Rapporto sulle azioni

Cap. di mercato: HK$2.5b

Venus Medtech (Hangzhou) Gestione

Gestione criteri di controllo 1/4

Venus Medtech (Hangzhou) Il CEO è Lin Haosheng Lim, nominato in Dec2016, e ha un mandato di 7.17 anni. la retribuzione annua totale è CN¥ 1.26M, composta da 85.4% di stipendio e 14.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.72% delle azioni della società, per un valore di HK$ 17.67M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.9 anni e 2.9 anni.

Informazioni chiave

Lin Haosheng Lim

Amministratore delegato

CN¥1.3m

Compenso totale

Percentuale dello stipendio del CEO85.4%
Mandato del CEO7.2yrs
Proprietà del CEO0.7%
Durata media del management1.9yrs
Durata media del Consiglio di amministrazione2.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?

Oct 05
Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?

Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?

May 29
Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?

What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You

May 11
What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You

Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Apr 07
Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

Oct 12
Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

Sep 04
Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

Jul 28
We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Mar 29
Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Jan 09
Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

Dec 01
Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

Aug 16
We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

Jul 12
A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth

Apr 26
Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth

Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%

Apr 05
Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%

Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate

Mar 07
Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate

What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?

Feb 14
What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?

Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner

Jan 19
Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner

Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?

Dec 29
Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?

Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?

Dec 29
Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?

Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?

Dec 08
Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Lin Haosheng Lim rispetto agli utili di Venus Medtech (Hangzhou)?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2023n/an/a

-CN¥1b

Mar 31 2023n/an/a

-CN¥1b

Dec 31 2022CN¥1mCN¥1m

-CN¥1b

Sep 30 2022n/an/a

-CN¥759m

Jun 30 2022n/an/a

-CN¥461m

Mar 31 2022n/an/a

-CN¥417m

Dec 31 2021CN¥1mCN¥694k

-CN¥374m

Compensazione vs Mercato: La retribuzione totale di Lin Haosheng ($USD 175.50K ) è inferiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 361.88K ).

Compensazione vs guadagni: La retribuzione di Lin Haosheng è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Lin Haosheng Lim (49 yo)

7.2yrs

Mandato

CN¥1,263,000

Compensazione

Mr. Hou-Sen Lim, also known as Lin Haosheng, MEng. Co-founded Transcatheter Technologies GmbH in 2009 and serves as its Managing Director and Chief Technology Officer. He serves as Chief Operating Officer...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Hou-Sen Lim
GM, COO & CTO7.2yrsCN¥1.26m0.72%
HK$ 17.7m
Fei Wang
Chief Financial Officerless than a yearNessun datoNessun dato
Joyce Heo
Director of Sales1.9yrsNessun datoNessun dato
Christopher Richardson
Head of U.S. Operations4.6yrsNessun datoNessun dato
Amir Gross
Head of Venus Global Heart Valve Innovation Center1.9yrsNessun datoNessun dato
Shakeel Osman
Senior Vice President of Sales Europe1.9yrsNessun datoNessun dato
Liu Meirong
Executive Director1.1yrsNessun datoNessun dato
Liqiao Ma
Executive Directorless than a yearNessun dato0.0084%
HK$ 208.0k
Wai Chiu Wong
Company Secretary3.1yrsNessun datoNessun dato

1.9yrs

Durata media

49yo

Età media

Gestione esperta: Il team dirigenziale di 2500 non è considerato esperto (durata media 1.9 anni), il che suggerisce un nuovo team.


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Liu Meirong
Executive Director1.1yrsNessun datoNessun dato
Liqiao Ma
Executive Directorless than a yearNessun dato0.0084%
HK$ 208.0k
Martin B. Leon
Member of Advisory Boardno dataNessun datoNessun dato
Chaim Lotan
Member of Global Advisory Board4.1yrsNessun datoNessun dato
Ting Yuk Wu
Independent Non-Executive Director5.3yrsCN¥423.00kNessun dato
Chi Wai Suen
Independent Non-Executive Director4.6yrsCN¥335.00kNessun dato
Wei Wang
Shareholders Representative Supervisor5.3yrsNessun datoNessun dato
Scott Lim
Member of Global Advisory Board4.1yrsNessun datoNessun dato
Min Shao
Employee Representative Supervisor1.5yrsNessun datoNessun dato
Zhang Ao
Non-Executive Director1.1yrsNessun datoNessun dato
Yue Li
Shareholders Representative Supervisor1.8yrsNessun datoNessun dato

2.9yrs

Durata media

48yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 2500 non è considerato esperto (durata media del mandato 2.9 anni), il che suggerisce un nuovo consiglio.